新的β-内酰胺/β-内酰胺酶抑制剂组合对革兰氏阴性菌的药敏试验的方方面面。
The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.
机构信息
Alberta Precision Laboratories, Calgary, Alberta, Canada.
Department of Pathology and Laboratory Medicine, University of Calgarygrid.22072.35, Calgary, Alberta, Canada.
出版信息
J Clin Microbiol. 2022 Jul 20;60(7):e0080721. doi: 10.1128/jcm.00807-21. Epub 2022 Apr 7.
Abstract
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are among the newest β-lactam/β-lactamase inhibitors (BL/BLIs) introduced to the North American antibiotic market. All have broad Gram-negative activity, including against certain carbapenemases. Despite this, susceptibility testing is warranted due to variable activity against certain β-lactamases (e.g., oxacillinases) and the presence of acquired resistance mechanisms in some isolates. Here, we discuss what we know about these new antimicrobial agents and how to navigate implementation of susceptibility testing and reporting of these agents in clinical laboratories.
摘要
头孢他啶-阿维巴坦、美罗培南-比阿培南和亚胺培南-雷利巴坦是北美抗生素市场推出的最新β-内酰胺/β-内酰胺酶抑制剂 (BL/BLIs) 之一。所有这些药物都对革兰氏阴性菌具有广泛的活性，包括某些碳青霉烯酶。尽管如此，由于对某些β-内酰胺酶（例如，氧头孢烯酶）的活性不同，以及某些分离株存在获得性耐药机制，仍需要进行药敏试验。在这里，我们讨论了我们对这些新的抗菌药物的了解，以及如何在临床实验室中进行药敏试验的实施和这些药物的报告。
相似文献
1
The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.新的β-内酰胺/β-内酰胺酶抑制剂组合对革兰氏阴性菌的药敏试验的方方面面。
J Clin Microbiol. 2022 Jul 20;60(7):e0080721. doi: 10.1128/jcm.00807-21. Epub 2022 Apr 7.
2
Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.头孢他啶-阿维巴坦对产 KPC-2 的肠杆菌科的抗菌活性：雷巴他定和沃巴他定联合用药及剂量递增滴定研究。
Microbiol Spectr. 2024 Jun 4;12(6):e0034424. doi: 10.1128/spectrum.00344-24. Epub 2024 Apr 30.
3
Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in .新型β-内酰胺/β-内酰胺酶抑制剂复方制剂和头孢地尔在 …… 中小碳青霉烯酶对其敏感性的影响
Antimicrob Agents Chemother. 2023 May 17;67(5):e0007823. doi: 10.1128/aac.00078-23. Epub 2023 Apr 11.
4
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.新型β-内酰胺/β-内酰胺酶抑制剂联合制剂对产丝氨酸碳青霉烯酶的碳青霉烯类耐药铜绿假单胞菌的活性。
J Antimicrob Chemother. 2023 Dec 1;78(12):2795-2800. doi: 10.1093/jac/dkad225.
5
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.头孢他啶/阿维巴坦、美罗培南/沃巴坦和亚胺培南/雷利巴坦对美国医院碳青霉烯酶阴性碳青霉烯类耐药肠杆菌科分离株的活性。
Int J Antimicrob Agents. 2021 Nov;58(5):106439. doi: 10.1016/j.ijantimicag.2021.106439. Epub 2021 Sep 20.
6
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.表型、基因型和断点：评估 OXA-48 对β-内酰胺/β-内酰胺酶抑制剂组合的作用。
J Antimicrob Chemother. 2022 Sep 30;77(10):2622-2631. doi: 10.1093/jac/dkac074.
7
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.头孢地尔肟与新型β-内酰胺/β-内酰胺酶抑制剂组合对高、低通透性条件下表达单种和双种β-内酰胺酶的同源大肠埃希菌的活性。
Int J Antimicrob Agents. 2024 May;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Epub 2024 Mar 19.
8
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.表型、基因型和断点：评估针对 OXA-48 的β-内酰胺/β-内酰胺酶抑制剂组合。
J Antimicrob Chemother. 2023 Mar 2;78(3):636-645. doi: 10.1093/jac/dkac425.
9
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).新型β-内酰胺/β-内酰胺酶抑制剂组合对来自美国医疗中心的铜绿假单胞菌分离株的比较活性（2020 - 2021年）
Int J Antimicrob Agents. 2023 Apr;61(4):106744. doi: 10.1016/j.ijantimicag.2023.106744. Epub 2023 Feb 3.
10
activity of cefiderocol against European and spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.头孢地尔罗对欧洲肠杆菌科和铜绿假单胞菌的活性，包括对美罗培南和最近的β-内酰胺/β-内酰胺酶抑制剂组合耐药的分离株。
Microbiol Spectr. 2024 Apr 2;12(4):e0383623. doi: 10.1128/spectrum.03836-23. Epub 2024 Mar 14.
引用本文的文献
1
Laboratory detection of carbapenemases among Gram-negative organisms.革兰氏阴性菌中碳青霉烯酶的实验室检测
Clin Microbiol Rev. 2024 Dec 10;37(4):e0005422. doi: 10.1128/cmr.00054-22. Epub 2024 Nov 15.
2
In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing .氨曲南与头孢他啶/阿维巴坦、美罗培南/伏巴拉坦和亚胺培南/瑞来巴坦联合对产双碳青霉烯酶菌株的体外协同和杀菌作用
Infect Drug Resist. 2024 Sep 4;17:3851-3861. doi: 10.2147/IDR.S474150. eCollection 2024.
3
Rates of resistance and heteroresistance to newer β-lactam/β-lactamase inhibitors for carbapenem-resistant Enterobacterales.耐碳青霉烯类肠杆菌科细菌对新型β-内酰胺/β-内酰胺酶抑制剂的耐药率和异质性耐药率。
JAC Antimicrob Resist. 2024 Mar 21;6(2):dlae048. doi: 10.1093/jacamr/dlae048. eCollection 2024 Apr.
4
What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review.β-内酰胺酶抑制剂的最佳药代动力学/药效学目标是什么？系统评价。
J Antimicrob Chemother. 2024 May 2;79(5):946-958. doi: 10.1093/jac/dkae058.
本文引用的文献
1
Erratum for Yahav et al., "New β-Lactam-β-Lactamase Inhibitor Combinations".雅哈夫等人所著《新型β-内酰胺-β-内酰胺酶抑制剂组合》的勘误
Clin Microbiol Rev. 2021 Jan 27;34(2). doi: 10.1128/CMR.00021-21. Print 2021 Mar 17.
2
New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.新型碳青霉烯酶抑制剂：为β-内酰胺类药物开辟道路。
Int J Mol Sci. 2020 Dec 6;21(23):9308. doi: 10.3390/ijms21239308.
3
Multicenter Evaluation of Ceftazidime-Avibactam Susceptibility Testing of and Pseudomonas aeruginosa on the Vitek 2 System.多中心评估头孢他啶-阿维巴坦药敏试验对 Vitek 2 系统中鲍曼不动杆菌和铜绿假单胞菌的影响。
J Clin Microbiol. 2021 Feb 18;59(3). doi: 10.1128/JCM.01870-20.
4
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会关于产超广谱β-内酰胺酶肠杆菌科（ESBL-E）、耐碳青霉烯肠杆菌科（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的治疗指南。
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478.
5
Imipenem-Relebactam Susceptibility Testing of Gram-Negative Bacilli by Agar Dilution, Disk Diffusion, and Gradient Strip Methods Compared with Broth Microdilution.与肉汤微量稀释法相比，采用琼脂稀释法、纸片扩散法和梯度条法对革兰氏阴性杆菌进行亚胺培南-瑞来巴坦药敏试验
J Clin Microbiol. 2020 Sep 22;58(10). doi: 10.1128/JCM.00695-20.
6
Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China.评估 Etest 和纸片扩散法检测头孢他啶-阿维巴坦对中国肠杆菌科和铜绿假单胞菌的活性。
BMC Microbiol. 2020 Jun 29;20(1):187. doi: 10.1186/s12866-020-01870-z.
7
Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.美罗培南-雷巴他定对来自美国的耐碳青霉烯大肠埃希菌分离株的活性与克隆背景、耐药基因、共同耐药性和地区的关系
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02408-19.
8
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.亚胺培南-西司他丁-瑞来巴坦：一种用于治疗多重耐药革兰氏阴性菌感染的新型β-内酰胺-β-内酰胺酶抑制剂组合。
Pharmacotherapy. 2020 Apr;40(4):343-356. doi: 10.1002/phar.2378. Epub 2020 Mar 9.
9
Resistance to ceftazidime-avibactam and underlying mechanisms.对头孢他啶-阿维巴坦的耐药性及其机制。
J Glob Antimicrob Resist. 2020 Sep;22:18-27. doi: 10.1016/j.jgar.2019.12.009. Epub 2019 Dec 19.
10
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.亚胺培南-雷巴坦对大量铜绿假单胞菌临床分离株和同源β-内酰胺耐药突变株的活性。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.02165-19.
Zotero 插件